Compass Pathways Plc’s shares plummeted after its psychedelic drug to treat a form of depression disappointed investors in a late-stage trial. The company said its psilocybin drug reduced depression ...
Compass shares crash as ‘confounding’ survival data raise approvability questions for bispecific
While tovecimig met the main goal of progression-free survival in a Phase 2/3 trial, it did not improve overall survival.
Hosted on MSN
Compass Pathways Stock Slumps After Positive Late-Stage Trial Results From Psychedelic Drug ‘Underwhelm’ Analysts
Shares of Compass Pathways Plc. (CMPS) slumped 47% on Monday afternoon after the results from the late-stage trials of COMP360 in treatment-resistant depression fell short of market expectations.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results